Chardan Capital Says uniQure (QURE) on Pullback, Slight Delay to AMT-060 is Immaterial

Go back to Chardan Capital Says uniQure (QURE) on Pullback, Slight Delay to AMT-060 is Immaterial

uniQure (QURE) Ests and PT Cut After Dropping Glybera - Jefferies

December 1, 2015 9:49 AM EST

Jefferies analyst, Eun Yang, reduced the price target on uniQure BV (NASDAQ: QURE) to $36 vs $40 previously. The drop takes into account the loss of revenue from the removal of Glybera and increasing the discount rate to 13% (from 12%) to reflect yet-to-be proven commercial potential/success of gene therapy products. No change to... More

uniQure BV (QURE) Sell-Off 'Unfounded' - Oppenheimer

December 1, 2015 7:11 AM EST

Oppenheimer Christopher Marai views yesterday's nearly 17% sell-off in uniQure BV (NASDAQ: QURE) unfounded. As such, the firm reiterated an Outperform rating and price target of $50.

uniQure reported 3Q15, ending the quarter with $215M in cash.

Marai commented, "Importantly, QURE clarified the... More

Janney Capital Starts uniQure BV (QURE) at Buy

November 30, 2015 5:10 PM EST

Janney Capital initiated coverage on uniQure BV (NASDAQ: QURE) with a Buy rating and a price target of $40.00.

For an analyst ratings summary and ratings history on uniQure BV click here. For more ratings news on uniQure BV click here.

Shares of uniQure BV closed at $22.50 yesterday.

... More